IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- IO Biotech presents new data on its lead therapeutic cancer vaccine candidate, IO102-IO103, in a pivotal Phase 3 study
- IO Biotech also presents new pre-clinical data for IO112, the next candidate in its pipeline
- None.
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), to be held in San Diego, California on November 1-5, 2023. Two of the posters will include new in vivo and in vitro data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study. The third poster contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.
Poster Presentations
Title: T Cell Receptor Diversity Analysis of in vitro-Expanded T cells Against IDO1 and PD-L1-Derived Peptides
Abstract Number: 1029
Presenter: Preeyam Patel, PhD, Senior Scientist, IO Biotech
Date: Friday, November 3, 2023
Location and time: Poster Hall: 9:00 a.m.– 7:00 p.m. PDT; Poster session Lunch 12:00 –1.30 p.m.; Poster reception 5:10 – 6:40 p.m.
Title: Peptide vaccination against PD-L1 reduces tumor growth in preclinical models through stimulation of PD-L1-targeting T cells in the tumor microenvironment
Abstract Number: 1468
Presenter: Marion Chapellier, PhD, Senior Scientist, IO Biotech
Date: Saturday, November 4, 2023
Location and time: Poster Hall: 9:00 a.m.– 8.30 p.m. PDT; Poster session lunch 11:55 a.m. – 1:25 p.m.; Poster reception 7:00 – 8.30 p.m.
Title: Arginase-1 vaccine promotes T cell immunity against arginase 1+ cells, controls tumor growth via immune modulation of tumor microenvironment
Abstract Number: 1335
Presenter: Marco Carretta, PhD, Senior Scientist, IO Biotech
Date: Friday, November 3, 2023
Location and time: Poster Hall: 9 a.m.– 7 p.m. PDT; Poster session lunch 12:00 – 1.30 p.m.; Poster reception 5:10 – 6:40 p.m.
About IO102-IO103
IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced non-small cell lung cancer and head and neck cancer, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) evaluating IO102-IO103 plus pembrolizumab as a perioperative treatment in solid tumors including Melanoma and Squamous Cell Carcinoma of Head and Neck (SCCHN). The clinical trial is sponsored by IO Biotech and conducted in collaboration with Merck. IO Biotech maintains global commercial rights to IO102-IO103.
About IOB-032/PN-E40 Phase 2 Basket Trial in Solid Tumors
IOB-032/PN-E40, (NCT05280314) is a multi-center, multi-arm basket trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment. This proof-of-concept trial will be focused initially on two indications and will include patients with resectable tumors in Melanoma and SCCHN.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® vaccine platform. The T-win platform is a novel approach to cancer vaccines designed to activate T cells to target the most important immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing in clinical studies its lead cancer vaccine candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates. Based on positive Phase 1/2 data, IO102-IO103 has been granted break through designation by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim analysis of our Phase 3 trial, current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
